Haemonetics Corp.
Haemonetics (NYSE: HAE) is a global medical technology company supplying products and software for plasma collection, blood centers and hospitals. Its Plasma segment provides automated source-plasma collection systems, disposable supplies and donor-management software to plasma collection centers and biopharmaceutical… From the company’s description.
Over the twelve months to Sep 26, 2026, Haemonetics Corp. reported revenue of $1.38B, up 4.1% from a year earlier, and net income of $103.91M. Its operating margin was 12.8%, and operations generated $344.93M in cash. In fiscal 2025, it reported revenue of $1.33B, down 2.0% from fiscal 2024, and net income of $97.31M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Haemonetics Corp. does
In the company’s own words
Haemonetics (NYSE: HAE) is a global medical technology company supplying products and software for plasma collection, blood centers and hospitals. Its Plasma segment provides automated source-plasma collection systems, disposable supplies and donor-management software to plasma collection centers and biopharmaceutical companies. Blood Center offers apheresis equipment and related products for blood collection organizations, including systems for collecting platelets and plasma. Hospital serves clinicians and healthcare facilities through Interventional Technologies, including vascular-closure devices, sensor-guided technologies and esophageal-protection systems, and Blood Management Technologies, including hemostasis diagnostics, cell-salvage systems and transfusion-management software. In fiscal 2026, Plasma generated 39.3% of revenue, Blood Center 16.6% and Hospital 44.1%. Products include NexSys PCS and NexLynk DMS for plasma collection, MCS apheresis equipment, VASCADE vascular-closure devices, TEG hemostasis systems and Cell Saver blood-recovery systems. The company sells in approximately 90 countries through direct sales and distributors; its customers include biopharmaceutical companies, blood collection organizations, hospitals and healthcare service providers.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- BOSTON, MA
- Fiscal year end
- April
- CIK
- 313143
- SIC
- 3841
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Haemonetics Corp. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Haemonetics Corp.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Haemonetics Corp.’s bonds, as funds hold them
Funds report holding 1 issues of Haemonetics Corp.’s debt, $161.49M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.50%, maturing 2029 to 2029.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Haemonetics Corp. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Haemonetics Corp.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Haemonetics Corp.'s last four quarterly filings that the numbers alone won't show?”